查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813426

2032 年医药化学品市场预测：按化学类型、治疗领域、最终用户和地区进行的全球分析

Pharmaceutical Chemicals Market Forecasts to 2032 - Global Analysis By Chemical Type (Active Pharmaceutical Ingredients (APIs), Excipients, Intermediates, Solvents and Reagents), Therapeutic Area, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球医药化学品市场预计在 2025 年达到 1,353.2 亿美元，到 2032 年将达到 2,274.5 亿美元，预测期内复合年增长率为 7.7%。

医药化学品是当今医疗治疗的重要基础。它们由活性药物成分 (API)、中间体和辅料组成，每种成分在药物生产中发挥不同的作用。 API 发挥主要的治疗作用，而中间体则在 API 的合成过程中充当过渡化合物。辅料透过改善非活性成分、稳定性、口感、吸收和持续时间来增强药效。透过为片剂、糖浆、胶囊和注射剂提供可靠的原料，我们的医药化学物品部门确保了药品的品质和功效。最终，这些化学物质对全球医疗保健至关重要，支持疾病管理、康復和改善健康。

根据国际製药商协会联合会 (IFPMA) 的数据，目前全球有超过 9,000 种化学化合物正在开发中，这一数字凸显了药物研发的规模之大，其中化学合成和配方在推动治疗方法创新方面发挥着重要作用。

学名药需求不断成长

对学名药日益增长的依赖是医药化学品行业的主要驱动力。随着专利到期，製造商面临开发价格合理且与原厂药具有相同疗效的替代药物的压力。这导致对原料药、中间体和辅料的需求增加，以确保药物製剂的品质和可靠性。各国政府和医疗保健组织正积极鼓励采用学名药，以降低医疗成本并提高病患的便利性。因此，医药化学品的生产正在迅速扩张。生产商需要提供可靠的高品质原料，而学名药浪潮是刺激该市场成长的关键因素。

製造和研发成本高

高昂的製造和研发成本是医药化学品产业的一大障碍。创造新的原料药、中间体和辅料需要最先进的基础设施、专业知识和昂贵的原料。监管申报、临床试验和安全研究进一步加重了这个过程的负担，所有这些都增加了支出。日益激烈的学名药竞争往往会降低盈利，阻碍许多公司在创新方面进行大规模投资。中小企业面临的风险最大，因为它们缺乏长期研究所需的财务稳定性。因此，新化合物的引入仍然有限，减缓了市场扩张，并增加了对大型资源丰富的公司的依赖。

在新兴市场扩张

新兴经济体为医药化学品市场成长提供了巨大的机会。亚太、非洲和拉丁美洲各国收入不断增长，医疗设施不断扩大，人口不断增长，推动了药品需求的不断增长。价格实惠的学名药在这些地区占据主导地位，对原料药、中间体和辅料的需求强劲。许多政府优先发展本地生产以减少进口，这为医药化学品供应商提供了在该地区立足的机会。与国内製药公司的合作进一步鼓励了跨国公司进入这些快速成长的地区。随着医疗保健支出和医疗可近性的不断提高，新兴市场为医药化学品行业的长期扩张提供了巨大的潜力。

市场竞争激烈

激烈的竞争对医药化学品产业构成了重大威胁。众多区域和国际公司争夺原料药、中间体和辅料的供应，迫使各公司在保持高品质的同时降低价格。学名药製造商的崛起进一步加剧了竞争，因为医疗保健系统更青睐价格更低的替代品。这种情况降低了利润率，并减少了用于研发和创新的资金。中小企业面临的风险最大，因为它们缺乏跨国公司的规模和资源。随着市占率争夺战的加剧，保持盈利和独特性变得更加困难，这对寻求保持竞争力的医药化学品製造商来说是一个长期挑战。

COVID-19的影响：

新冠疫情危机对医药化学品产业造成了重大影响。供应链中断导致原料药、中间体和其他原料的运输延误，扰乱了许多製药商的生产。同时，疫苗、抗病毒药物和支持性治疗的需求激增，为化学品供应商创造了巨大的商机。企业必须迅速调整产能，实施严格的安全措施，并满足不断变化的监管要求。疫情在带来营运和物流障碍的同时，也刺激了技术创新，增加了对医药研发的投资，并凸显了医药化学品在医疗保健体系中的关键作用。这段时期既凸显了该产业在全球卫生紧急事件中的脆弱性，也凸显了其战略重要性。

循环系统领域预计将成为预测期内最大的领域

预计循环系统领域将在预测期内占据最大的市场份额。在全球范围内，高血压、心肌梗塞和中风等心血管疾病的发生率不断上升，推动了相关药物的持续需求。药物研发的进步，例如联合治疗和耐受性更高的製剂，进一步推动了这项需求。此外，随着全球人口老化，对心血管治疗的需求也不断增长。这一趋势推动了对心血管特异性活性化合物和中间体合成的持续投资。因此，心血管治疗领域将继续成为医药化学品行业收入的最大贡献者。

预计预测期内受託製造厂商(CMO) 部门的复合年增长率最高。

预计受託製造厂商(CMO) 细分市场将在预测期内实现最高成长率。这种快速成长源于製药公司越来越多地将其製造业务外包给 CMO，以降低成本、提高生产效率并专注于研发和行销。此外，CMO 还提供活性药物成分 (API) 合成、配方开发、品质保证和包装等专业服务，由于对经济实惠、可扩展且可靠的製药製造解决方案的需求不断增长，这些服务的需求也日益旺盛。

占比最大的地区：

预计北美将在预测期内占据最大的市场份额。这一领先地位得益于其集中的知名製药公司、先进的研发设施和完善的医疗保健体系。美国凭藉其众多经营大型生产工厂和研发中心的大型主要企业而脱颖而出。此外，有利的专利法和智慧财产权保护也正在推动该地区的创新。北美专注于开发新型疗法和生物标记物，并严格遵守美国食品药物管理局 (FDA) 等机构强制执行的品质标准，巩固了其在医药化学品领域的主导地位。

复合年增长率最高的地区：

预计亚太地区在预测期内将实现最高的复合年增长率。主要驱动因素包括医疗保健支出的增加、製药产能的扩张以及新兴经济体对活性药物成分 (API) 日益增长的需求。中国和印度等国家正在推动这一成长，这得益于其在研发方面的大量投资以及强劲的製药业。此外，该地区人口众多且老化，加上慢性病的发病率上升，这些因素都刺激了对医药化学品的需求。因此，预计亚太地区未来几年将出现显着的市场成长。

免费客製化服务

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球医药化学品市场（依化学类型）

  • 活性药物成分（API）
    • 合成 API
    • 生物技术 API
  • 辅料
  • 中间体
  • 溶剂
  • 试剂

6. 全球医药化学品市场（依治疗领域）

  • 肿瘤学
  • 心血管系统
  • 中枢神经系统（CNS）
  • 感染疾病
  • 内分泌学
  • 呼吸系统
  • 皮肤科
  • 胃肠病学
  • 其他治疗领域

7. 全球医药化学品市场（依最终用户划分）

  • 製药商
  • 契约製造组织（CMO）
  • 药物研究与开发研究所
  • 化学品供应商和经销商

8. 全球医药化学品市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第九章：主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章：企业概况

  • Sun Pharma
  • Dr. Reddy's Labs
  • Aurobindo Pharma
  • Cipla
  • Zydus Life
  • Lupin
  • Biocon
  • Glenmark Pharma
  • Alkem Lab
  • Torrent Pharma
  • Divis Labs
  • Piramal Pharma
  • Ipca Labs
  • Aarti Industries
  • Kajay Remedies
Product Code: SMRC30875

According to Stratistics MRC, the Global Pharmaceutical Chemicals Market is accounted for $135.32 billion in 2025 and is expected to reach $227.45 billion by 2032 growing at a CAGR of 7.7% during the forecast period. Pharmaceutical chemicals form the essential foundation of today's medical treatments. They consist of active pharmaceutical ingredients (APIs), intermediates, and excipients, each serving distinct functions in drug creation. APIs deliver the primary therapeutic action, while intermediates act as transitional compounds in the synthesis of these APIs. Excipients, although not medicinally active, enhance drug performance by improving stability, taste, absorption, and durability. By providing reliable raw materials for tablets, syrups, capsules, and injectable solutions, the pharmaceutical chemical sector ensures the quality and effectiveness of medications. Ultimately, these chemicals are indispensable to global healthcare, supporting disease management, recovery, and the improvement of human health.

According to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), there are currently over 9,000 compounds at different stages of development globally. This figure highlights the immense scale of pharmaceutical R&D, where chemical synthesis and formulation play a foundational role in advancing therapeutic innovation.

Market Dynamics:

Driver:

Rising demand for generic drugs

Growing reliance on generic medicines is strongly fueling the pharmaceutical chemicals industry. With patent expirations of leading drugs, manufacturers are compelled to develop affordable alternatives that maintain the same therapeutic effectiveness as branded options. To achieve this, there is heightened demand for APIs, intermediates, and excipients that ensure quality and reliability in drug formulations. Governments and healthcare organizations actively encourage generic adoption to lower medical expenses and enhance accessibility for patients. Consequently, the production of pharmaceutical chemicals is expanding rapidly. Producers must deliver reliable, high-standard raw materials, making the generic drug wave a pivotal factor stimulating growth in this market.

Restraint:

High production and R&D costs

High manufacturing and R&D expenses pose a considerable barrier in the pharmaceutical chemicals industry. Creating new APIs, intermediates, or excipients demands cutting-edge infrastructure, specialized knowledge, and costly raw materials. The process is further burdened by regulatory filings, clinical testing, and safety trials, all of which escalate spending. Profitability often suffers as rising generic competition reduces returns, leaving many companies hesitant to invest heavily in innovation. Small and medium enterprises face the greatest risk since they lack financial stability for long-term research. Consequently, the introduction of novel chemical entities remains limited, slowing market expansion and reinforcing reliance on larger corporations with robust resources.

Opportunity:

Expansion in emerging markets

Developing economies present vast opportunities for growth in the pharmaceutical chemicals market. Nations across Asia-Pacific, Africa, and Latin America are experiencing rising incomes, expanding healthcare facilities, and larger populations, fueling higher demand for medicines. Affordable generics dominate these regions, creating strong requirements for APIs, intermediates, and excipients. Many governments are prioritizing local manufacturing to minimize imports, giving suppliers of pharmaceutical chemicals a chance to establish themselves regionally. Partnerships with domestic pharmaceutical firms further support global companies in entering these fast-growing areas. As healthcare spending and accessibility rise, emerging markets offer significant potential for long-term expansion in the pharmaceutical chemicals industry.

Threat:

Intense market competition

Fierce rivalry significantly threatens the pharmaceutical chemicals sector. Numerous regional and international firms compete by supplying APIs, intermediates, and excipients, forcing companies to cut prices while ensuring high quality. The rise of generic drug manufacturers makes the competition even tougher, as healthcare systems favor cheaper alternatives. Such conditions erode profit margins, leaving fewer funds for research and innovation. Smaller companies face the greatest risk since they lack the scale and resources of global corporations. As the battle for market share grows, maintaining profitability and distinctiveness becomes more difficult, creating long-term challenges for pharmaceutical chemical producers trying to remain competitive.

Covid-19 Impact:

The COVID-19 crisis significantly influenced the pharmaceutical chemicals industry. Supply chain interruptions delayed shipments of APIs, intermediates, and other raw materials, disrupting production for numerous pharmaceutical manufacturers. Simultaneously, the sudden surge in demand for vaccines, antiviral medications, and supportive treatments generated substantial opportunities for chemical suppliers. Firms needed to rapidly adjust production capacities, implement strict safety measures, and meet evolving regulatory requirements. Although the pandemic introduced operational and logistical obstacles, it also spurred innovation, increased investments in pharmaceutical research and development, and emphasized the essential role of pharmaceutical chemicals in healthcare systems. This period demonstrated both the vulnerabilities and strategic importance of the industry during global health emergencies.

The cardiovascular segment is expected to be the largest during the forecast period

The cardiovascular segment is expected to account for the largest market share during the forecast period. The global rise in cardiovascular disorders-such as hypertension, myocardial infarction, and stroke-drives sustained demand for related medications. Advances in drug development, including combination therapies and formulations with enhanced tolerability, further boost this demand. Moreover, as populations age worldwide, the necessity for cardiovascular treatments grows stronger. These dynamics continuously funnel investment into the synthesis of cardiovascular-specific active compounds and intermediates. As a result, the cardiovascular therapeutic area remains the foremost contributor by revenue in the pharmaceutical chemicals sector.

The contract manufacturing organizations (CMOs) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the contract manufacturing organizations (CMOs) segment is predicted to witness the highest growth rate. This rapid growth stems from the increasing tendency of pharmaceutical companies to outsource manufacturing operations to CMOs to lower costs, enhance production efficiency, and focus on research, development, and marketing. Additionally, CMOs provide expert services including active pharmaceutical ingredient (API) synthesis, formulation development, quality assurance, and packaging, which are highly sought after due to the growing demand for affordable, scalable, and reliable drug manufacturing solutions.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. This leadership is driven by the concentration of prominent pharmaceutical firms, cutting-edge research and development facilities, and a well-established healthcare system. The United States stands out with its numerous leading pharmaceutical companies operating large-scale production plants and R&D hubs. Furthermore, favorable patent laws and intellectual property protections encourage innovation within the region. North America's emphasis on creating novel therapeutics and biomarkers, along with adherence to rigorous quality standards enforced by agencies such as the U.S. FDA, solidifies its dominant role in the pharmaceutical chemicals sector.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Key drivers include increased healthcare expenditure, the expansion of pharmaceutical manufacturing capacities, and a heightened need for active pharmaceutical ingredients (APIs) in developing economies. Nations such as China and India are leading this growth, bolstered by substantial investments in research and development and the presence of a robust pharmaceutical industry. Furthermore, the region's large and aging population, coupled with a rising incidence of chronic diseases, is fueling the demand for pharmaceutical chemicals. Consequently, the APAC region is poised for significant market growth in the coming years.

Key players in the market

Some of the key players in Pharmaceutical Chemicals Market include Sun Pharma, Dr. Reddy's Labs, Aurobindo Pharma, Cipla, Zydus Life, Lupin, Biocon, Glenmark Pharma, Alkem Lab, Torrent Pharma, Divis Labs, Piramal Pharma, Ipca Labs, Aarti Industries and Kajay Remedies.

Key Developments:

In July 2025, Sun Pharmaceutical Industries Ltd has announced that it has entered into a settlement and license agreement with Incyte Corporation regarding litigation related to LEQSELVI. Under the terms of agreement, the parties will seek dismissal of the pending LEQSELVI litigation in the United States District Court for the District of New Jersey and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation.

In February 2025, Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a daratumumab biosimilar candidate to Johnson & Johnson's (J&J) Darzalex & Darzalex Faspro. Darzalex & Darzalex Faspro are indicated to treat multiple myeloma. The partnership leverages Dr. Reddy's worldwide commercial network along with Henlius' expertise in biosimilar development.

In November 2024, Aurobindo Pharma's US faction has entered into collaboration and licensing agreement with a global pharmaceutical company. The agreement will focus on the development of respiratory therapeutics, with associated costs being shared equally between the partners. The development period is predicted to span around three to five years, with Aurobindo's total spend in this portion of the deal capped at USD $90m.

Chemical Types Covered:

  • Active Pharmaceutical Ingredients (APIs)
  • Excipients
  • Intermediates
  • Solvents
  • Reagents

Therapeutic Areas Covered:

  • Oncology
  • Cardiovascular
  • Central Nervous System (CNS)
  • Infectious Diseases
  • Endocrinology
  • Respiratory
  • Dermatology
  • Gastroenterology
  • Other Therapeutic Areas

End Users Covered:

  • Pharmaceutical Manufacturers
  • Contract Manufacturing Organizations (CMOs)
  • Pharmaceutical R&D Institutions
  • Chemical Suppliers & Distributors

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pharmaceutical Chemicals Market, By Chemical Type

  • 5.1 Introduction
  • 5.2 Active Pharmaceutical Ingredients (APIs)
    • 5.2.1 Synthetic APIs
    • 5.2.2 Biotech APIs
  • 5.3 Excipients
  • 5.4 Intermediates
  • 5.5 Solvents
  • 5.6 Reagents

6 Global Pharmaceutical Chemicals Market, By Therapeutic Area

  • 6.1 Introduction
  • 6.2 Oncology
  • 6.3 Cardiovascular
  • 6.4 Central Nervous System (CNS)
  • 6.5 Infectious Diseases
  • 6.6 Endocrinology
  • 6.7 Respiratory
  • 6.8 Dermatology
  • 6.9 Gastroenterology
  • 6.10 Other Therapeutic Areas

7 Global Pharmaceutical Chemicals Market, By End User

  • 7.1 Introduction
  • 7.2 Pharmaceutical Manufacturers
  • 7.3 Contract Manufacturing Organizations (CMOs)
  • 7.4 Pharmaceutical R&D Institutions
  • 7.5 Chemical Suppliers & Distributors

8 Global Pharmaceutical Chemicals Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Sun Pharma
  • 10.2 Dr. Reddy's Labs
  • 10.3 Aurobindo Pharma
  • 10.4 Cipla
  • 10.5 Zydus Life
  • 10.6 Lupin
  • 10.7 Biocon
  • 10.8 Glenmark Pharma
  • 10.9 Alkem Lab
  • 10.10 Torrent Pharma
  • 10.11 Divis Labs
  • 10.12 Piramal Pharma
  • 10.13 Ipca Labs
  • 10.14 Aarti Industries
  • 10.15 Kajay Remedies

List of Tables

  • Table 1 Global Pharmaceutical Chemicals Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Pharmaceutical Chemicals Market Outlook, By Chemical Type (2024-2032) ($MN)
  • Table 3 Global Pharmaceutical Chemicals Market Outlook, By Active Pharmaceutical Ingredients (APIs) (2024-2032) ($MN)
  • Table 4 Global Pharmaceutical Chemicals Market Outlook, By Synthetic APIs (2024-2032) ($MN)
  • Table 5 Global Pharmaceutical Chemicals Market Outlook, By Biotech APIs (2024-2032) ($MN)
  • Table 6 Global Pharmaceutical Chemicals Market Outlook, By Excipients (2024-2032) ($MN)
  • Table 7 Global Pharmaceutical Chemicals Market Outlook, By Intermediates (2024-2032) ($MN)
  • Table 8 Global Pharmaceutical Chemicals Market Outlook, By Solvents (2024-2032) ($MN)
  • Table 9 Global Pharmaceutical Chemicals Market Outlook, By Reagents (2024-2032) ($MN)
  • Table 10 Global Pharmaceutical Chemicals Market Outlook, By Therapeutic Area (2024-2032) ($MN)
  • Table 11 Global Pharmaceutical Chemicals Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 12 Global Pharmaceutical Chemicals Market Outlook, By Cardiovascular (2024-2032) ($MN)
  • Table 13 Global Pharmaceutical Chemicals Market Outlook, By Central Nervous System (CNS) (2024-2032) ($MN)
  • Table 14 Global Pharmaceutical Chemicals Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 15 Global Pharmaceutical Chemicals Market Outlook, By Endocrinology (2024-2032) ($MN)
  • Table 16 Global Pharmaceutical Chemicals Market Outlook, By Respiratory (2024-2032) ($MN)
  • Table 17 Global Pharmaceutical Chemicals Market Outlook, By Dermatology (2024-2032) ($MN)
  • Table 18 Global Pharmaceutical Chemicals Market Outlook, By Gastroenterology (2024-2032) ($MN)
  • Table 19 Global Pharmaceutical Chemicals Market Outlook, By Other Therapeutic Areas (2024-2032) ($MN)
  • Table 20 Global Pharmaceutical Chemicals Market Outlook, By End User (2024-2032) ($MN)
  • Table 21 Global Pharmaceutical Chemicals Market Outlook, By Pharmaceutical Manufacturers (2024-2032) ($MN)
  • Table 22 Global Pharmaceutical Chemicals Market Outlook, By Contract Manufacturing Organizations (CMOs) (2024-2032) ($MN)
  • Table 23 Global Pharmaceutical Chemicals Market Outlook, By Pharmaceutical R&D Institutions (2024-2032) ($MN)
  • Table 24 Global Pharmaceutical Chemicals Market Outlook, By Chemical Suppliers & Distributors (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.